Unity Biotechnology’s (UBX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX) in a research note published on Monday morning,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright also issued estimates for Unity Biotechnology’s Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at $0.23 EPS, FY2028 earnings at $0.68 EPS and FY2029 earnings at $0.88 EPS.

Separately, Chardan Capital assumed coverage on Unity Biotechnology in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock.

Unity Biotechnology Trading Up 3.5 %

UBX stock opened at $1.78 on Monday. The company has a market capitalization of $29.99 million, a PE ratio of -1.36 and a beta of 1.02. Unity Biotechnology has a 12-month low of $0.94 and a 12-month high of $3.10. The business’s fifty day moving average price is $1.88 and its 200 day moving average price is $1.51.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Unity Biotechnology stock. Bridgeway Capital Management LLC raised its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.30% of Unity Biotechnology worth $49,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.